PriceTargets.com logo

Arvinas - ARVN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $60.00
  • Forecasted Upside: 166.90%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 13 Buy Ratings
  • 0 Strong Buy Ratings
$22.48 As of 11/15/2024 01:00 AM ET
▼ -2.44 (-9.79%)

This chart shows the closing price for ARVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arvinas Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARVN

Analyst Price Target is $60.00
▲ +166.90% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Arvinas in the last 3 months. The average price target is $60.00, with a high forecast of $90.00 and a low forecast of $40.00. The average price target represents a 166.90% upside from the last price of $22.48.

This chart shows the closing price for ARVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 14 polled investment analysts is to moderate buy stock in Arvinas. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$87.00 ➝ $87.00
10/31/2024OppenheimerLower TargetOutperform ➝ Outperform$50.00 ➝ $40.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$87.00 ➝ $87.00
7/31/2024Cantor FitzgeraldReiterated RatingOverweight
7/31/2024BarclaysLower TargetOverweight ➝ Overweight$60.00 ➝ $48.00
7/31/2024OppenheimerLower TargetOutperform ➝ Outperform$70.00 ➝ $50.00
7/30/2024WedbushReiterated RatingOutperform ➝ Outperform$57.00 ➝ $57.00
5/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$87.00
5/9/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$63.00 ➝ $60.00
5/8/2024WedbushReiterated RatingOutperform ➝ Outperform$57.00
5/8/2024Stifel NicolausLower TargetBuy ➝ Buy$72.00 ➝ $68.00
5/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$87.00
4/12/2024HC WainwrightLower TargetBuy ➝ Buy$90.00 ➝ $87.00
3/25/2024Truist FinancialReiterated RatingBuy ➝ Buy$65.00
2/29/2024BarclaysBoost TargetOverweight ➝ Overweight$26.00 ➝ $60.00
2/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00
2/28/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$89.00 ➝ $90.00
2/28/2024OppenheimerReiterated RatingOutperform ➝ Outperform$95.00 ➝ $80.00
2/28/2024WedbushBoost TargetOutperform ➝ Outperform$33.00 ➝ $59.00
2/22/2024Leerink PartnrsReiterated RatingOutperform
2/14/2024CitigroupDowngradeBuy ➝ Neutral$36.00 ➝ $55.00
2/1/2024The Goldman Sachs GroupInitiated CoverageBuy$70.00
12/19/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$25.00 ➝ $63.00
12/6/2023Jefferies Financial GroupUpgradeHold ➝ Buy$32.00 ➝ $40.00
11/20/2023GuggenheimUpgradeNeutral ➝ Buy$40.00
11/13/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$32.00 ➝ $20.00
11/8/2023Stifel NicolausLower TargetBuy ➝ Buy$46.00 ➝ $42.00
10/24/2023CitigroupLower TargetBuy ➝ Buy$72.00 ➝ $36.00
10/24/2023BarclaysLower TargetOverweight ➝ Overweight$39.00 ➝ $26.00
10/23/2023Piper SandlerLower TargetOverweight ➝ Overweight$70.00 ➝ $55.00
10/23/2023WedbushUpgradeNeutral ➝ Outperform$27.00 ➝ $24.00
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$70.00
8/21/2023CitigroupLower TargetBuy ➝ Buy$77.00 ➝ $72.00
8/16/2023Truist FinancialReiterated RatingBuy ➝ Buy$65.00
8/14/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$35.00 ➝ $32.00
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$90.00
8/9/2023OppenheimerReiterated RatingOutperform ➝ Outperform$95.00
8/9/2023Piper SandlerLower Target$81.00 ➝ $70.00
8/8/2023BarclaysLower TargetOverweight ➝ Overweight$70.00 ➝ $39.00
5/8/2023Stifel NicolausLower Target$75.00 ➝ $72.00
3/17/2023CitigroupBoost Target$72.00 ➝ $77.00
2/27/2023Morgan StanleyLower TargetEqual Weight$57.00 ➝ $36.00
2/24/2023HC WainwrightReiterated RatingBuy$90.00
2/24/2023Credit Suisse GroupLower TargetOutperform$81.00 ➝ $61.00
1/31/2023Cantor FitzgeraldReiterated RatingOverweight$90.00
1/17/2023Truist FinancialLower TargetBuy$100.00 ➝ $65.00
1/12/2023GuggenheimDowngradeBuy ➝ Neutral
1/10/2023WedbushLower Target$43.00 ➝ $27.00
1/10/2023OppenheimerLower Target$102.00 ➝ $95.00
1/2/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$83.00 ➝ $49.00
12/5/2022CitigroupLower TargetBuy$88.00 ➝ $72.00
11/28/2022The Goldman Sachs GroupReiterated RatingBuy$81.00
11/23/2022Truist FinancialLower Target$170.00 ➝ $100.00
11/23/2022Cantor FitzgeraldLower Target$106.00 ➝ $90.00
11/23/2022BarclaysLower TargetOverweight$90.00 ➝ $70.00
11/22/2022Piper SandlerBoost TargetOverweight$76.00 ➝ $81.00
11/22/2022Leerink PartnersLower TargetOutperform$89.00 ➝ $74.00
11/15/2022Credit Suisse GroupBoost Target$81.00
11/11/2022Morgan StanleyLower TargetEqual Weight$63.00 ➝ $57.00
10/25/2022Capital One FinancialInitiated CoverageOverweight
10/18/2022Stifel NicolausReiterated RatingBuy ➝ Buy$80.00
9/21/2022Cantor FitzgeraldReiterated RatingOverweight
9/9/2022BarclaysInitiated CoverageOverweight$90.00
8/18/2022CitigroupLower Target$103.00 ➝ $88.00
8/8/2022OppenheimerLower TargetOutperform$108.00 ➝ $102.00
8/5/2022Cantor FitzgeraldLower Target$140.00 ➝ $115.00
8/5/2022Leerink PartnersLower TargetOutperform$91.00 ➝ $89.00
8/5/2022Credit Suisse GroupLower TargetOutperform$98.00 ➝ $78.00
8/5/2022HC WainwrightLower TargetBuy$135.00 ➝ $90.00
6/21/2022Jefferies Financial GroupInitiated CoverageHold$42.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$111.00 ➝ $89.00
5/23/2022Piper SandlerLower TargetOverweight$116.00 ➝ $76.00
5/20/2022CitigroupLower TargetBuy$103.00
5/9/2022WedbushDowngradeOutperform ➝ Neutral$43.00
5/5/2022Stifel EuropeLower TargetBuy ➝ Buy$85.00 ➝ $82.00
4/28/2022Credit Suisse GroupInitiated CoverageOutperform$104.00
4/26/2022Stifel NicolausLower Target$93.00 ➝ $85.00
4/6/2022Morgan StanleyInitiated CoverageEqual Weight$65.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
3/1/2022Stifel NicolausLower TargetBuy$100.00 ➝ $93.00
3/1/2022The Goldman Sachs GroupLower TargetBuy$157.00 ➝ $110.00
2/18/2022WedbushLower Target$115.00 ➝ $98.00
2/18/2022Leerink PartnersLower TargetOutperform$97.00 ➝ $91.00
2/10/2022Wells Fargo & CompanyInitiated CoverageOverweight$98.00
1/19/2022The Goldman Sachs GroupInitiated CoverageBuy$157.00
12/6/2021CowenInitiated CoverageOutperform
11/4/2021OppenheimerUpgradeMarket Perform ➝ Outperform
10/14/2021Leerink PartnersInitiated CoverageOutperform$115.00
9/29/2021Stifel NicolausInitiated CoverageBuy$115.00
9/9/2021Bank of AmericaInitiated CoverageBuy$110.00
8/9/2021Roth CapitalBoost TargetBuy$120.00 ➝ $135.00
8/5/2021Piper SandlerBoost TargetOverweight ➝ Overweight$105.00 ➝ $125.00
7/23/2021BMO Capital MarketsBoost TargetOutperform$101.00 ➝ $111.00
7/23/2021CitigroupBoost TargetBuy$118.00 ➝ $153.00
7/23/2021HC WainwrightReiterated RatingBuy$100.00 ➝ $135.00
7/23/2021OppenheimerBoost TargetOutperform$100.00 ➝ $108.00
7/22/2021Piper SandlerReiterated RatingOverweight$97.00 ➝ $105.00
7/22/2021Truist FinancialBoost TargetBuy$150.00 ➝ $170.00
5/20/2021UBS GroupInitiated CoverageBuy$123.00
4/21/2021Northern Trust Capital MarketsInitiated CoverageBuy
4/21/2021Truist FinancialInitiated CoverageBuy$150.00
3/31/2021BMO Capital MarketsInitiated CoverageOutperform$101.00
3/30/2021Cantor FitzgeraldBoost TargetOverweight$121.00 ➝ $140.00
1/19/2021OppenheimerBoost Target$80.00 ➝ $100.00
1/5/2021Cantor FitzgeraldBoost TargetOverweight$66.00 ➝ $121.00
12/21/2020Piper SandlerBoost TargetOverweight$58.00 ➝ $97.00
12/15/2020Smith Barney CitigroupBoost Target$43.00 ➝ $123.00
12/15/2020Roth CapitalBoost TargetBuy$65.00 ➝ $120.00
12/14/2020HC WainwrightReiterated RatingBuy$60.00 ➝ $100.00
12/14/2020BMO Capital MarketsBoost TargetOutperform$62.00 ➝ $114.00
12/14/2020OppenheimerUpgradeMarket Perform ➝ Outperform
12/14/2020The Goldman Sachs GroupBoost TargetBuy$78.00 ➝ $129.00
12/14/2020WedbushBoost TargetOutperform$62.00 ➝ $93.00
12/1/2020Cantor FitzgeraldLower Target$75.00 ➝ $66.00
10/9/2020Cantor FitzgeraldReiterated RatingOverweight
10/8/2020OppenheimerReiterated RatingHold
8/4/2020OppenheimerInitiated CoverageHold
6/1/2020CitigroupUpgradeNeutral ➝ Buy$45.00
5/31/2020OppenheimerInitiated CoverageHold
5/29/2020Cantor FitzgeraldReiterated RatingBuy$75.00
5/14/2020Cantor FitzgeraldReiterated RatingBuy$75.00
5/11/2020OppenheimerInitiated CoverageMarket Perform
5/4/2020Roth CapitalBoost TargetBuy$35.00 ➝ $65.00
4/29/2020HC WainwrightReiterated RatingBuy$50.00 ➝ $60.00
4/14/2020Cantor FitzgeraldReiterated RatingBuy$75.00
3/16/2020Piper SandlerReiterated RatingBuy$58.00
1/30/2020BMO Capital MarketsReiterated RatingOutperform$62.00
1/24/2020WedbushBoost TargetOutperform$39.00 ➝ $60.00
1/6/2020Piper Sandler CompaniesBoost TargetOverweight$35.00 ➝ $58.00
12/20/2019Cantor FitzgeraldBoost TargetOverweight$42.00 ➝ $75.00
12/19/2019HC WainwrightInitiated CoverageBuy$50.00
11/25/2019GuggenheimInitiated CoverageBuy$50.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 10 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
Mentions as of
5/21/2024
  • 19 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 13 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/19/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 10 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 8 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 8 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Arvinas logo
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Read More

Today's Range

Now: $22.48
Low: $22.46
High: $25.10

50 Day Range

MA: $25.78
Low: $22.48
High: $28.04

52 Week Range

Now: $22.48
Low: $19.31
High: $53.08

Volume

677,590 shs

Average Volume

636,521 shs

Market Capitalization

$1.54 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Arvinas?

The following Wall Street research analysts have issued reports on Arvinas in the last year: Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Leerink Partnrs, Oppenheimer Holdings Inc., Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist Financial Co., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for ARVN.

What is the current price target for Arvinas?

0 Wall Street analysts have set twelve-month price targets for Arvinas in the last year. Their average twelve-month price target is $60.00, suggesting a possible upside of 166.9%. BMO Capital Markets has the highest price target set, predicting ARVN will reach $90.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $40.00 for Arvinas in the next year.
View the latest price targets for ARVN.

What is the current consensus analyst rating for Arvinas?

Arvinas currently has 1 hold rating and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ARVN.

What other companies compete with Arvinas?

Other companies that are similar to Arvinas include Syndax Pharmaceuticals, Pliant Therapeutics, Annexon, Morphic and Enanta Pharmaceuticals. Learn More about companies similar to Arvinas.

How do I contact Arvinas' investor relations team?

Arvinas' physical mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company's listed phone number is (203) 535-1456 and its investor relations email address is [email protected]. The official website for Arvinas is www.arvinas.com. Learn More about contacing Arvinas investor relations.